Newest
PEBO ▼ sold $76K · Augenstein Mark filed 1d agoBBT ▲ bought $105K · Hollister Thomas J filed 2d agoBBT ▼ sold $20K · Eagan John Buckley filed 2d agoGS ▼ sold $60K · LESLIE ERICKA T filed 2d agoGS ▼ sold $163K · LESLIE ERICKA T filed 2d agoMSCI ▼ sold $1.5M · Gutowski Robert J. filed 2d agoGL ▼ sold $2.2M · MAJORS MICHAEL CLAY filed 2d agoPHR ▲ bought $362 · Linetsky David filed 2d agoPHR ▲ bought $320 · Linetsky David filed 2d agoRVI ▲ bought $23K · Whitney Meredith filed 2d agoLEO ▲ bought $369K · Saba Capital Management, L.P. filed 2d agoPG ▼ sold $5.7M · Jejurikar Shailesh filed 2d agoICLR ▼ sold $10K · Lyons Emer filed 2d agoICLR ▼ sold $10K · Lyons Emer filed 2d agoICLR ▼ sold $8K · Lyons Emer filed 2d agoICLR ▼ sold $15K · Lyons Emer filed 2d agoICLR ▼ sold $8K · Lyons Emer filed 2d agoPG ▼ sold $698K · Gama Paul filed 2d ago

Company / CIK 0001818382

Humacyte, Inc.

Ticker
HUMA
Size, estimated from filings
Micro cap (under $300M)
Insiders on file
9
Members of Congress who traded it
1
Federal contracts on record
none matched
Lobbying filings on record
7
SEC filings
EDGAR ↗
Latest trade on record
October 6, 2026

Humacyte, Inc. (HUMA) has 9 insiders on file who disclosed 12 transactions in the last 12 months (3 open-market buys, 0 sales, about $30K at reported prices), and 5 congressional trades in its stock are on record. No federal contract award that started in the last 180 days was found for a recipient with exactly this name, and 3 lobbying filings naming it as client report $150K in 2026.

Last updated October 21, 2026 · Sources: SEC EDGAR; USAspending; Senate LDA

Humacyte, Inc. in charts

Who is trading this stock

Which people account for the buying and selling over the last 12 months?

BoughtSold

1 person accounts for the disclosed buying and selling in Humacyte, Inc. over the last 12 months; the most active is Jones Keith Anthony with $30K.

Lobbying spend by quarter

How much has Humacyte, Inc. reported spending on federal lobbying?

Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26
Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26

Humacyte, Inc. reported $250K in lobbying over the last eight quarters, from filings matched by exact company name.

Insiders

NameRoleRowsBoughtSoldLast filed
COWARD D SCOTTDirector100October 7, 2026
Kuznik Paul BrianDirector100October 7, 2026
Jones Keith AnthonyDirector430September 15, 2026
Windham-Bannister Susan RichardsDirector100June 12, 2026
Constantino Michael T.Director100June 12, 2026
Wallace Max N.Director100June 12, 2026
Niklason Laura EPresident, CEO and Director100June 12, 2026
Sebelius KathleenDirector100June 12, 2026
Green Charles BruceDirector100June 12, 2026

Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.

Members of Congress who traded HUMA

From periodic transaction reports that name the company's stock. Amounts are the sums of the ranges as filed. Every row is on the HUMA page.

MemberSeatTradesBoughtSoldRange as filedLatest
Tommy TubervilleSenator (AL), Republican532$33K–$145KMay 3, 2024

Insider transactions

Download CSV17 rows · 6 KB · insider and congressional rows for this ticker · all downloads

FilerSecuritySideTrade dateDisclosedLagSharesPriceValueFlagsSourceShare
Kuznik Paul BrianHUMAOther AOctober 6, 2026October 7, 20261d125,000——derivativeForm 4 ↗
COWARD D SCOTTHUMAOther AOctober 6, 2026October 7, 20261d125,000——derivativeForm 4 ↗
Jones Keith AnthonyHUMABuy PSeptember 14, 2026September 15, 20261d10,000$1$5,620Form 4 ↗
Jones Keith AnthonyHUMABuy PAugust 20, 2026August 21, 20261d10,000$1$6,930Form 4 ↗
Jones Keith AnthonyHUMABuy PAugust 17, 2026August 19, 20262d30,000$1$18KForm 4 ↗
Green Charles BruceHUMAOther AJune 11, 2026June 12, 20261d80,000——derivativeForm 4 ↗
Jones Keith AnthonyHUMAOther AJune 11, 2026June 12, 20261d80,000——derivativeForm 4 ↗
Sebelius KathleenHUMAOther AJune 11, 2026June 12, 20261d80,000——derivativeForm 4 ↗
Niklason Laura EHUMAOther AJune 11, 2026June 12, 20261d80,000——indirectderivativeForm 4 ↗
Wallace Max N.HUMAOther AJune 11, 2026June 12, 20261d80,000——derivativeForm 4 ↗
Constantino Michael T.HUMAOther AJune 11, 2026June 12, 20261d80,000——derivativeForm 4 ↗
Windham-Bannister Susan RichardsHUMAOther AJune 11, 2026June 12, 20261d80,000——derivativeForm 4 ↗

Federal contracts (USAspending, awards started in the last 180 days)

No contract award starting in the last 180 days was found for a recipient named exactly "Humacyte, Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.

Lobbying (Senate LDA, as client)

PeriodRegistrantPrimary issueAmountSource
2026 Q3CAPITOL HILL CONSULTING GROUPMedicare/Medicaid$50,000LDA ↗
2026 Q2CAPITOL HILL CONSULTING GROUPMedicare/Medicaid$50,000LDA ↗
2026 Q1CAPITOL HILL CONSULTING GROUPMedicare/Medicaid$50,000LDA ↗
2025 Q4CAPITOL HILL CONSULTING GROUPMedicare/Medicaid$50,000LDA ↗
2025 Q3CAPITOL HILL CONSULTING GROUPMedicare/Medicaid$50,000LDA ↗
2025 Q3CAPITOL HILL CONSULTING GROUPHealth Issues—LDA ↗
2025 Q3G2G CONSULTINGHealth Issues—LDA ↗

Companies whose stock was traded by the same people who traded HUMA, by number of filers in common. It shows overlap in public filings and nothing else.

Guides for this page

Sources and method

Official sources behind this page
SourceFilingsRowsFirst filedNewest filedRead the originals
Senate eFD, periodic transaction reports25August 5, 2026August 5, 2026Senate eFD search
SEC EDGAR, Form 41212June 12, 2026October 7, 2026Form 4 list on EDGAR
Lobbying disclosure filings7 filings———LDA.gov search

Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.

Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.

Not investment advice. Public records shown as filed; no recommendation is made or implied.